Analytical Method For Increasing Susceptibility Of Molecular Targeted Therapy In Hepatocellular Carcinoma

Abstract

Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFRβ, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.


Claims
Download PDF
Document Preview
Document History
  • Publication: Jul 10, 2018
  • Application: Apr 16, 2014
    US US 201414765304 A
  • Priority: Apr 16, 2014
    KR KR 2014003281 W
  • Priority: Apr 25, 2013
    KR KR 20130046279 A

Download Citation


Sign in to the Lens

Feedback